Douglas R Cary
Overview
Explore the profile of Douglas R Cary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi K, Uehara S, Yamamoto S, Cary D, Nishikawa J, Ueda T, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1093-1101.
PMID: 34267879
Nicotinamide -methyltransferase (NNMT), which catalyzes the methylation of nicotinamide, is a cytosolic enzyme that has attracted much attention as a therapeutic target for a variety of diseases. However, despite the...
2.
Kurasaki H, Nagaya A, Kobayashi Y, Matsuda A, Matsumoto M, Morimoto K, et al.
Org Lett
. 2020 Oct;
22(20):8039-8043.
PMID: 33006475
Sustainable and efficient manufacturing methods for -methylated peptides remain underexplored despite growing interest in therapeutic -methylated peptides within the pharmaceutical industry. A methodology for the coupling of -terminally unprotected -methylamino...
3.
Nakao S, Nogami M, Iwatani M, Imaeda T, Ito M, Tanaka T, et al.
Biochem Biophys Res Commun
. 2020 Jan;
523(3):795-801.
PMID: 31954521
The DEAD-box family of RNA helicases plays essential roles in both transcriptional and translational mRNA degradation; they unwind short double-stranded RNA by breaking the RNA-RNA interactions. Two DEAD-box RNA helicases,...
4.
Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, et al.
ACS Med Chem Lett
. 2019 Oct;
10(10):1498-1503.
PMID: 31620240
General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies...
5.
Nakayama K, Szewczyk M, Dela Sena C, Wu H, Dong A, Zeng H, et al.
Oncotarget
. 2018 May;
9(26):18480-18493.
PMID: 29719619
Protein arginine methyltransferase (PRMT) 4 (also known as coactivator-associated arginine methyltransferase 1; CARM1) is involved in a variety of biological processes and is considered as a candidate oncogene owing to...
6.
Mizojiri R, Nakata D, Satoh Y, Morishita D, Shibata S, Iwatani-Yoshihara M, et al.
ACS Med Chem Lett
. 2017 Oct;
8(10):1077-1082.
PMID: 29057054
Starting from our previous eIF4A3-selective inhibitor , a novel series of (piperazine-1-carbonyl)pyridin-2(1)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds and showed improved physicochemical...
7.
Fujimoto J, Hirayama T, Hirata Y, Hikichi Y, Murai S, Hasegawa M, et al.
Bioorg Med Chem
. 2017 Apr;
25(12):3018-3033.
PMID: 28392276
In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various...
8.
Ito M, Tanaka T, Cary D, Iwatani-Yoshihara M, Kamada Y, Kawamoto T, et al.
J Med Chem
. 2017 Mar;
60(8):3335-3351.
PMID: 28358513
Eukaryotic initiation factor 4A3 (eIF4A3), a member of the DEAD-box RNA helicase family, is one of the core components of the exon junction complex (EJC). The EJC is known to...
9.
Ono K, Banno H, Okaniwa M, Hirayama T, Iwamura N, Hikichi Y, et al.
Bioorg Med Chem
. 2017 Mar;
25(8):2336-2350.
PMID: 28302507
To develop a novel series of CDK8/19 dual inhibitors, we employed structure-based drug design using docking models based on a library compound, 4,5-dihydroimidazolo[3',4':3,4]benzo[1,2-d]isothiazole 16 bound to CDK8. We designed various...
10.
Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary D, et al.
ACS Med Chem Lett
. 2014 Jun;
4(2):201-5.
PMID: 24900643
The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers. Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR...